Literature DB >> 18268270

Moving from opacity to transparency in pharmaceutical policy.

Irfan Dhalla1, Andreas Laupacis.   

Abstract

Mesh：

Year:  2008        PMID： 18268270      PMCID： PMC2228347          DOI： 10.1503/cmaj.070799

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  20 in total

1.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson; Mette T Haahr; Peter C Gøtzsche; Douglas G Altman
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

2.  Failing the public health--rofecoxib, Merck, and the FDA.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-10-06       Impact factor: 91.245

3.  Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness?

Authors:  Michael Drummond
Journal:  Appl Health Econ Health Policy       Date:  2002       Impact factor: 2.561

4.  Clinical practice guidelines and conflict of interest.

Authors: 
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

5.  Exorcising ghosts and unwelcome guests.

Authors:  Christine Laine; Cynthia D Mulrow
Journal:  Ann Intern Med       Date:  2005-10-18       Impact factor: 25.391

6.  Pharmacies receiving massive rebates from generic drug-makers.

Authors:  Ann Silversides
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

7.  On bias and transparency in the development of influential recommendations.

Authors:  Andreas Laupacis
Journal:  CMAJ       Date:  2006-01-31       Impact factor: 8.262

8.  Publication bias in clinical research.

Authors:  P J Easterbrook; J A Berlin; R Gopalan; D R Matthews
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

Review 9.  Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Authors:  Mike Tierney; Braden Manns
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

10.  Conflict of interest in the debate over calcium-channel antagonists.

Authors:  H T Stelfox; G Chua; K O'Rourke; A S Detsky
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245
View more
  14 in total

1.  The power of "principles" in a national pharmaceuticals strategy.

Authors:  Catherine S Macpherson; Nuala P Kenny
Journal:  Healthc Policy       Date:  2009-02

2.  Use of product listing agreements by Canadian provincial drug benefit plans.

Authors:  Steven G Morgan; Melissa K Friesen; Paige A Thomson; Jamie R Daw
Journal:  Healthc Policy       Date:  2013-05

3.  Will Open Government make Canada's health agencies more transparent?

Authors:  Paul C Hébert; Jane Coutts; Matthew B Stanbrook; Noni MacDonald; Ken Flegel
Journal:  CMAJ       Date:  2011-03-21       Impact factor: 8.262

4.  Cost shifting and timeliness of drug formulary decisions in atlantic Canada.

Authors:  Andrea C Scobie; Neil J Mackinnon
Journal:  Healthc Policy       Date:  2010-02

5.  Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.

Authors:  Matthew Herder
Journal:  CMAJ       Date:  2011-08-29       Impact factor: 8.262

6.  Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.

Authors:  Jacqui Miot; Monika Wagner; Hanane Khoury; Donna Rindress; Mireille M Goetghebeur
Journal:  Cost Eff Resour Alloc       Date:  2012-02-29

Review 7.  Regulating prescription drugs for patient safety: does Bill C-17 go far enough?

Authors:  Matthew Herder; Elaine Gibson; Janice Graham; Joel Lexchin; Barbara Mintzes
Journal:  CMAJ       Date:  2014-03-10       Impact factor: 8.262

8.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08

9.  Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.

Authors:  Michèle Tony; Monika Wagner; Hanane Khoury; Donna Rindress; Tina Papastavros; Paul Oh; Mireille M Goetghebeur
Journal:  BMC Health Serv Res       Date:  2011-11-30       Impact factor: 2.655

10.  The timing of drug funding announcements relative to elections: a case study involving dementia medications.

Authors:  Sudeep S Gill; Neeraj Gupta; Chaim M Bell; Paula A Rochon; Peter C Austin; Andreas Laupacis
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.